Supernus Pharmaceuticals Analyst Ratings
Supernus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/23/2023 | 16.6% | Piper Sandler | $40 → $47 | Maintains | Overweight |
| 08/31/2022 | -5.73% | Piper Sandler | $33 → $38 | Maintains | Overweight |
| 04/13/2021 | -0.77% | Jefferies | $25 → $40 | Upgrades | Hold → Buy |
| 06/16/2020 | -23.1% | Piper Sandler | $25 → $31 | Upgrades | Neutral → Overweight |
| 06/15/2020 | -40.46% | Jefferies | → $24 | Reinstates | → Hold |
| 04/16/2020 | -40.46% | Stifel | $25 → $24 | Maintains | Hold |
| 11/07/2019 | -42.94% | Stifel | $55 → $23 | Downgrades | Buy → Hold |
| 11/06/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/17/2018 | 56.29% | Mizuho | $61 → $63 | Maintains | Buy |
| 11/12/2018 | 61.25% | B. Riley Securities | $68 → $65 | Maintains | Buy |
| 09/18/2018 | 51.33% | Mizuho | → $61 | Initiates Coverage On | → Buy |
| 08/09/2018 | 43.88% | Jefferies | $55 → $58 | Maintains | Buy |
| 05/25/2018 | 48.85% | Stifel | $50 → $60 | Maintains | Buy |
| 02/01/2018 | 63.73% | Berenberg | → $66 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/23/2023 | 16.6% | 吹笛者桑德勒 | 四十美元 → 47 美元 | 維護 | 超重 |
| 2022 年 8 月 31 日 | -5.73% | 吹笛者桑德勒 | 三十三元 → 三八美元 | 維護 | 超重 |
| 2021 年 4 月 13 日 | -0.77% | 富瑞集團 | 25 美元 → 40 美元 | 升級 | 持有 → 購買 |
| 2020 年 06 月 16 日 | -23.1% | 吹笛者桑德勒 | 25 美元 → 31 美元 | 升級 | 中性 → 超重 |
| 06/15/2020 | -40.46% | 富瑞集團 | → 二十四美元 | 恢復 | → 保持 |
| 04/16/2020 | -40.46% | 斯蒂弗 | 25 美元 → 24 美元 | 維護 | 保持 |
| 11/07/2019 | -42.94% | 斯蒂弗 | 三十五美元 → 23 美元 | 降級 | 購買 → 持有 |
| 11/06/2019 | — | 富瑞集團 | 降級 | 購買 → 持有 | |
| 12/17/2018 | 56.29% | 瑞穗市 | 六一元 → 63 美元 | 維護 | 購買 |
| 11/12/2018 | 61.25% | B. 萊利證券 | 六十八元 → 六十五美元 | 維護 | 購買 |
| 09/18/2018 | 51.33% | 瑞穗市 | → 六一美元 | 啟動覆蓋範圍 | → 購買 |
| 2018 年 9 月 8 日 | 43.88% | 富瑞集團 | 五十五美元 → 58 美元 | 維護 | 購買 |
| 05/25/2018 | 48.85% | 斯蒂弗 | 五十元 → 六十元 | 維護 | 購買 |
| 02/01/2018 | 63.73% | 貝倫伯格 | → 66 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for Supernus Pharmaceuticals (SUPN)?
超新藥品（SUPN）的目標價格是多少？
The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on January 23, 2023. The analyst firm set a price target for $47.00 expecting SUPN to rise to within 12 months (a possible 16.60% upside). 2 analyst firms have reported ratings in the last year.
派珀·桑德勒於 2023 年 1 月 23 日報導了超級努斯製藥（納斯達克股票代碼：SUPN）的最新價格目標。該分析師公司設定了 47.00 美元的價格目標，預計 SUPN 將在 12 個月內上升（可能的上漲 16.60％）。2 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?
超新藥業（SUPN）的最新分析師評級是什麼？
The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.
Supernus 製藥公司（納斯達克股票代碼：SUPN）的最新分析師評級由派珀·桑德勒提供，超級藥品保持其超重評級。
When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?
Supernus 製藥公司（SUPN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.
分析師在進行了廣泛的研究後抵達股票評級，其中包括通過公共財務報表，與 Supernus Pharmacharmacery 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。對於 Supernus 製藥的最後評級已於 2023 年 1 月 23 日提交，因此您應該期望下一個評級將在 2024 年 1 月 23 日左右提供。
Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?
分析師評級超級藥品（SUPN）是否正確？
While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $40.00 to $47.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $40.31, which is within the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的超級藥品（SUPN）評級保持在 40.00 美元至 47.00 美元的目標價格。目前的價格超級藥品（SUPN）的交易價格為 $40.31，這是在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。